{"generic":"Retapamulin","drugs":["Altabax","Retapamulin"],"mono":{"0":{"id":"928774-s-0","title":"Generic Names","mono":"Retapamulin"},"1":{"id":"928774-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928774-s-1-4","title":"Adult Dosing","mono":"<b>Impetigo, Due to Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes:<\/b> apply thin layer TOPICALLY to affected area twice daily for 5 days; treated area may be covered with sterile bandage or gauze dressing "},"1":{"id":"928774-s-1-5","title":"Pediatric Dosing","mono":"<b>Impetigo, Due to Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes:<\/b> (9 months or older) apply thin layer TOPICALLY to affected area twice daily for 5 days; treated area may be covered with sterile bandage or gauze dressing "},"3":{"id":"928774-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Impetigo, Due to Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes<br\/>"}}},"3":{"id":"928774-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928774-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928774-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole); not recommended in patients younger than 2 years<\/li><li>sensitization or severe local irritation may occur; discontinue use<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928774-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"928774-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928774-s-4","title":"Drug Interactions","sub":{"1":{"id":"928774-s-4-14","title":"Major","mono":"<ul><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}}},"5":{"id":"928774-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Application site irritation (adults, 1.6%)<br\/><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Allergic reaction<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"928774-s-6","title":"Drug Name Info","sub":{"0":{"id":"928774-s-6-17","title":"US Trade Names","mono":"Altabax<br\/>"},"2":{"id":"928774-s-6-19","title":"Class","mono":"Antibacterial<br\/>"},"3":{"id":"928774-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928774-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928774-s-7","title":"Mechanism Of Action","mono":"Retapamulin is a semisynthetic derivative of the compound pleuromutilin with antibacterial properties. Bacterial protein synthesis is selectively inhibited by interactions at the 50S ribosomal subunit involving ribosomal protein L3 which inhibit peptidyl transfer, block P-site interactions, and prevent the normal creation of active 50S ribosomal subunits.<br\/>"},"8":{"id":"928774-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928774-s-8-24","title":"Distribution","mono":"Protein binding: 94% <br\/>"},"2":{"id":"928774-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: extensive by CYP3A4<\/li><li>substrate of CYP3A4<\/li><\/ul>"}}},"9":{"id":"928774-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>for external use only<\/li><li>do not use in the eyes, on the mouth or lips, inside the nose, or inside the female genital area<\/li><\/ul>"},"10":{"id":"928774-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement within 3 to 4 days of starting therapy<\/li><li>application site irritation<\/li><\/ul>"},"11":{"id":"928774-s-11","title":"How Supplied","mono":"<b>Altabax<\/b><br\/>Topical Ointment: 1 %<br\/>"},"13":{"id":"928774-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug is not for ingestion, or for oral, intranasal, ophthalmic, or intravaginal use.<\/li><li>Instruct patient to notify a healthcare professional if no improvement is seen within 3 to 4 days, or if the area of application worsens (irritation, redness, itching, burning, swelling, blistering, or oozing).<\/li><li>Patient and caregivers should wash their hands after application, unless the hands are to be treated.<\/li><li>Recommend that the patient cover the treated area with a sterile bandage or gauze dressing after applying the ointment.<\/li><\/ul>"}}}